Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. - Wikidata - awgldk - TriplyDB

Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.

Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.

http://www.wikidata.org/entity/Q34451427

about

Alternative Donor Transplantation for Acute Myeloid Leukemia Fifty years of melphalan use in hematopoietic stem cell transplantation Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes.Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.Donor-derived second hematologic malignancies after cord blood transplantation.Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.Umbilical cord blood transplantation: the first 25 years and beyond.Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study.The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation.Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults.Enhancing engraftment of cord blood cells via insight into the biology of stem/progenitor cell function.In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children.Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.Characteristics of chronic GVHD after cord blood transplantation.Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.Background and future considerations for human cord blood hematopoietic cell transplantation, including economic concerns.Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.The expanding frontier of hematopoietic cell transplantation.New strategies in cord blood cells transplantation.Umbilical cord blood transplantation: review of factors affecting the hospitalized patient.Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.Umbilical cord blood donation: public or private?Cord blood transplant for acute myeloid leukaemia.

P2860

Q26799456-DFBAC66C-B0AD-4793-81D5-CA9C263A0C12 Q26824498-D5AA2D51-4A2D-4308-A3EE-6E4B1C4F1990 Q30415126-6A14AD17-2927-4D02-A880-5B0DF41AA516 Q30418861-5A4627C5-A9FD-439A-93E3-DA6CC48C5E27 Q33847973-232AB36E-BC9D-46A4-8272-A94DE4A7712C Q33952705-BF3679B8-B916-4150-BE17-ADEFDFDEE4ED Q34077792-2173C757-C5BD-412F-B33C-4413AF6EC49A Q34344669-FB8313B4-0E2C-4A37-B888-D99C107DF911 Q34463602-CC16514C-C621-400B-BCA5-8583CBDF0A57 Q34551183-F9964988-9280-469B-8473-840611B6C943 Q35108791-A7730D97-B6FA-4964-AE24-D56DD3786AE0 Q35202366-6D1997B6-D4C4-41F5-BEAA-32E3D28225E5 Q35608181-DF09E21E-2866-4075-A032-4292964B1062 Q35692767-DD512AFA-3C85-40B0-9A17-60DB20922FEF Q36192813-4BA850E2-3596-4C76-8E10-F5D24D853071 Q36264735-13001A7A-258B-40B5-A4CE-01B6EE532318 Q36395129-91949E0E-CD89-4F49-98AA-9113853D0C15 Q36702752-F345AEB9-82C6-4EA4-B351-4416C37192C7 Q36746512-12E85157-AED5-4877-8B3E-2780D4C4FE94 Q36777485-98ECFF4B-8A7E-418B-8FF2-1D4C92DE7F1A Q36905573-93027794-3818-4C41-90DA-85B29E6C7EBC Q36905580-5A9B04F9-8187-4273-AF21-627E3B3BC518 Q36923436-132F5CF3-FB2F-4742-B1FA-8A9D683093F8 Q37216236-35C4598C-5389-4D8E-8B24-3B63E9ACF8E3 Q37227600-41E0791D-6534-4171-927D-A07909AD0CE9 Q37263182-0E4A684C-62E5-40EB-88B6-35498F6ACB4E Q37276889-1679397A-F74C-4BEE-8DA3-D48C19A34EA3 Q37391113-0A463C0F-B7C5-4C7F-9B07-DBDA6C95BEBB Q37443125-46C652A4-3CD2-4BED-BBA2-231BD4E93254 Q37621636-7202A364-F614-45FA-9C3A-6F74C378F754 Q37675185-01581AB1-80B9-41DC-A3E4-E43A43689DBD Q37685590-92E84918-08C0-4465-BFDE-50B55F93E0B6 Q38010596-4A34D59B-1E98-423D-B68F-57A0BFD7A6DB Q38032255-49D17E6F-4208-470E-A2B6-47722E416416 Q38099291-65CD64CC-E36E-475E-B8B4-5C33131E6427 Q38113482-3C8884DD-7862-467F-8631-7767CE358717 Q38387292-D4C1B7F6-798C-45E6-A68A-22173BBE807A Q38416371-8D2AAE22-0D04-455E-B397-3EAC5DE96C7F Q38510475-6843A029-7CF7-4121-8867-7ECA9A0BFF4C Q38696346-D5DDD63B-25C0-438F-8966-A9FA5718F4A9

P2860

Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.

http://www.wikidata.org/entity/Q34451427

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Double umbilical cord blood tr ...... olimus-based GVHD prophylaxis.

@ast

Double umbilical cord blood tr ...... olimus-based GVHD prophylaxis.

@en

Double umbilical cord blood tr ...... olimus-based GVHD prophylaxis.

@nl

type

label

Double umbilical cord blood tr ...... olimus-based GVHD prophylaxis.

@ast

Double umbilical cord blood tr ...... olimus-based GVHD prophylaxis.

@en

Double umbilical cord blood tr ...... olimus-based GVHD prophylaxis.

@nl

prefLabel

Double umbilical cord blood tr ...... olimus-based GVHD prophylaxis.

@ast

Double umbilical cord blood tr ...... olimus-based GVHD prophylaxis.

@en

Double umbilical cord blood tr ...... olimus-based GVHD prophylaxis.

@nl

P1433

Q34451427-F3A05B76-6C85-4630-8064-F0A2AD870E5F

P1476

Q34451427-B94871D1-857D-4789-845A-E40B99077DD1

P2093

Q34451427-04D80493-5136-44C2-B51F-D27BD873014D

Q34451427-16A1C21C-33D3-46C1-9738-25AB8A5120F7

Q34451427-1F55E3F2-8C0E-4764-B870-F7343A209CF6

Q34451427-1FBE23FE-D239-4422-95D9-4BACF64640A4

Q34451427-3FDE74D4-2524-4DDF-AC34-CAAAAD023901

Q34451427-401D78C2-CFB9-4647-9C84-E2285D0D88CC

Q34451427-4358CA96-4F7A-49E2-BEB4-8E550AB3D61C

Q34451427-517C2378-5419-42E7-BC45-8BDE1D0483A7

Q34451427-7C55EA92-B4D7-47C2-816B-3766AC7F2D3D

Q34451427-8241195B-6E36-4E76-81CF-E3392AAC35F8

P2860

Q34451427-047E3DD2-35B8-49B8-91CA-F710B0D0827F

Q34451427-146AEB8C-0656-4CCE-ABAE-615415DC1615

Q34451427-1AB048BA-CF77-4798-98E8-DDE3A16C2FB9

Q34451427-1C6B0027-3F9F-4798-BD78-F4C7AC96B535

Q34451427-1E1EDD7C-FAC5-4B9B-A50F-7AA2D4885F73

Q34451427-2188DF8B-7551-4442-87BD-73CA36ABA133

Q34451427-34592711-5D5D-4666-A262-53F19DF0E188

Q34451427-3B3680F1-FCB5-4CCE-980C-DA494DD1938E

Q34451427-5C83B465-3FD5-462E-8C32-CBFBA6143696

Q34451427-5FE85ADA-24D5-483C-A591-688913DEE720

P2888

Q34451427-23D84563-2B1D-4148-95D2-B3127412AD16

P304

Q34451427-F0A83E4F-2C38-43F5-8934-5B8FD83E53F1

P31

Q34451427-B7F2936F-82A2-4A31-B554-7386EA003AF4

P356

Q34451427-1F556D0B-F8FE-4890-A490-3E8CB323B40D

P407

Q34451427-9A80E606-A156-4989-9E46-D220B9E7C91F

P433

Q34451427-C819F06C-7E69-4A03-9675-4C2523860C70

P478

Q34451427-3768D176-A6AD-4A62-9D7F-05C84FA3FB3E

P50

Q34451427-46F7DF99-C0F8-4D79-BF82-F7A9346F45C2

P577

Q34451427-74538EAE-B4B4-42AA-89C7-2CCA5E1B4C5C

P5875

Q34451427-A88EBE98-8A03-4400-AB34-73FD7C693AF8

P6179

Q34451427-20934B0F-3F76-42C8-817F-C15A94B5ED71

P698

Q34451427-D63E3DF5-91CF-4A37-B71A-23F8B60C3993

P932

Q34451427-D8FCA03F-5849-438E-95AA-B2BCD6819834

P356

P1433

Bone Marrow Transplantation

P1476

Double umbilical cord blood tr ...... rolimus-based GVHD prophylaxis

@en

P2093

B R Dey

http://www.w3.org/2001/XMLSchema#string

C Cutler

http://www.w3.org/2001/XMLSchema#string

C Reynolds

http://www.w3.org/2001/XMLSchema#string

D Liney

http://www.w3.org/2001/XMLSchema#string

E Alyea

http://www.w3.org/2001/XMLSchema#string

E Attar

http://www.w3.org/2001/XMLSchema#string

G Kao

http://www.w3.org/2001/XMLSchema#string

H T Kim

http://www.w3.org/2001/XMLSchema#string

J Brown

http://www.w3.org/2001/XMLSchema#string

J H Antin

http://www.w3.org/2001/XMLSchema#string

P2860

Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.

Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.

Double unrelated reduced-intensity umbilical cord blood transplantation in adults.

The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.

Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas.

Sirolimus: its discovery, biological properties, and mechanism of action.

Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.

Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.

P2888

P304

659-667

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2010.192

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45583801

http://www.w3.org/2001/XMLSchema#string

P6179

1029379948

http://www.w3.org/2001/XMLSchema#string

P698

20697368

http://www.w3.org/2001/XMLSchema#string

P932

3012740

http://www.w3.org/2001/XMLSchema#string